This review discusses the coexistence of heart failure with preserved ejection fraction and tricuspid regurgitation, suggesting possible management strategies including transcatheter treatments.
This review highlights the frequent coexistence of HFpEF and tricuspid regurgitation, suggesting that management of one condition may impact the pathophysiology and outcomes of the other.
Heart failure with preserved ejection fraction (HFpEF) is associated with high morbidity and mortality. Important risk factors for the development of HFpEF are similar to risk factors for the progression of tricuspid regurgitation (TR), and both conditions frequently coexist and thus is a distinct phenotype or a marker for advanced HF. Many patients with severe, symptomatic atrial secondary TR have been enrolled in current transcatheter device trials, and may represent patients at an advanced stage of HFpEF. Management of HFpEF thus may affect the pathophysiology of TR, and the physiologic changes that occur following transcatheter treatment of TR, may also impact symptoms and outcomes in patients with HFpEF. This review discusses these issues and suggests possible management strategies for these patients.
Hahn et al. (2024) conducted a review in Heart failure with preserved ejection fraction (HFpEF) and tricuspid regurgitation (TR). Management strategies and transcatheter treatment was evaluated. This review discusses the coexistence of heart failure with preserved ejection fraction and tricuspid regurgitation, suggesting possible management strategies including transcatheter treatments.